{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.9","upperLimit":"57.9","value":"39.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR at 6 cycles if the patient met the MMR criteria at the Cycle 6 Visit.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients resistant or intolerant to either imatinib or dasatinib","id":"OG000","title":"Resistant/Intolerant Ph+ CML in CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"6 cycles","title":"Rate of Major Molecular Response (MMR) at 6 Cycles for Ph+ CML CP Patients Resistant or Intolerant to Imatinib or Dasatinib","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}